Pharma company Alembic gets benefit on obtaining EIR for panel formulation facility.
The stock touched its 52-week high level of Rs 2,265 and the 52-week low level 1,693 on September 10, 2018 and March 25, 2019.
After receiving the EIR from the USFDA by the company, Alkem Laboratories shares increased by 1 percent on Friday, making the company a good profit.
According to BSE, the company has received the Installation Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for inspection done in its formulation facility in the panel during the period 22 to 25 October 2018.
10:45 am Alchem Laboratories was bidding on BSE at Rs 1,760, Rs 16.50 or 0.95 percent.
The stock touched its 52-week high level of Rs 2,265 and the 52-week low level 1,693 on September 10, 2018 and March 25, 2019.
Currently, it is down 22.3 percent from its 52-week high level and its 52-week bottom level is up 3.96 percent.
For more stock market news,you can also like our facebook page.click here
 |
| Pharma company Alembic |
The stock touched its 52-week high level of Rs 2,265 and the 52-week low level 1,693 on September 10, 2018 and March 25, 2019.
After receiving the EIR from the USFDA by the company, Alkem Laboratories shares increased by 1 percent on Friday, making the company a good profit.
According to BSE, the company has received the Installation Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for inspection done in its formulation facility in the panel during the period 22 to 25 October 2018.
10:45 am Alchem Laboratories was bidding on BSE at Rs 1,760, Rs 16.50 or 0.95 percent.
The stock touched its 52-week high level of Rs 2,265 and the 52-week low level 1,693 on September 10, 2018 and March 25, 2019.
Currently, it is down 22.3 percent from its 52-week high level and its 52-week bottom level is up 3.96 percent.
For more stock market news,you can also like our facebook page.click here
No comments:
Post a Comment